An article published on The Lancet Infectious Diseases shows that Sinovac's COVID-19 vaccine induces a quick immune response. According to Bloomberg, Sinovac vaccine clinical trials in Indonesia showed no serious adverse effects on subjects as of November 6. Sinovac is currently running three Phase III trials in Indonesia, Brazil and Turkey.